{"id":783048,"date":"2023-09-11T10:21:14","date_gmt":"2023-09-11T14:21:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-appoints-caroline-loewy-to-board-of-directors\/"},"modified":"2023-09-11T10:21:14","modified_gmt":"2023-09-11T14:21:14","slug":"effector-therapeutics-appoints-caroline-loewy-to-board-of-directors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-appoints-caroline-loewy-to-board-of-directors\/","title":{"rendered":"eFFECTOR Therapeutics Appoints Caroline Loewy to Board of Directors"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Sept.  11, 2023  (GLOBE NEWSWIRE) &#8212; eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (\u201cSTRIs\u201d) for the treatment of cancer, today announced the addition of Caroline Loewy to its Board of Directors and her election as Chair of the Board\u2019s Audit Committee. Concurrent with Ms. Loewy\u2019s appointment, current Board member John Smither has resigned from the Board.<\/p>\n<p>\u201cWe are tremendously fortunate to welcome Caroline given her extensive experience as an executive and board member at multiple biopharmaceutical companies,\u201d remarked Steve Worland, Ph.D., president and chief executive officer of eFFECTOR. \u201cBeyond her previous C-suite roles in operations and finance, Caroline also brings to eFFECTOR a wealth of senior analytical and governance experience, having served as an equity research analyst and chair of the Audit Committee at several companies. Her breadth of expertise will provide invaluable insight as we push towards prospective registrational trials and commercialization of our pipeline of selective translation regulator inhibitors. At the same time, on behalf of the entire eFFECTOR team and the Board, I would like to express our utmost gratitude to John for his invaluable contributions to eFFECTOR.\u201d<\/p>\n<p>\u201cI look forward to working with the management team and other Board members at eFFECTOR,\u201d said Ms. Loewy. \u201cWith two assets in Phase 2 clinical trials with upcoming data readouts, this is an auspicious time for the company, with the potential for significant value creation and pipeline advancement.\u201d<\/p>\n<p>\u201cI would like to thank Steve and the rest of the board for the opportunity to serve eFFECTOR,\u201d added Mr. Smither. \u201cI have appreciated the innovation and dedication of eFFECTOR team members that has brought the company to its current position and am confident in their continued execution going forward.\u201d<\/p>\n<p>With over 25 years of biopharmaceutical and financial executive experience, Ms. Loewy presently acts independently in providing strategic advisory services to biopharmaceutical companies. Ms. Loewy was a cofounder and the Chief Business Officer and Chief Financial Officer of Achieve Life Sciences, prior to its acquisition by OncoGenex Pharmaceuticals, Inc. in 2017. Prior to Achieve, Ms. Loewy previously served as Chief Financial Officer of both public and private biopharmaceutical companies including Tobira Therapeutics, acquired by Allergan Inc. in 2016, Corcept Therapeutics and Poniard Pharmaceuticals. In addition to her biopharmaceutical executive roles, Ms. Loewy also served 11 years as a senior biotechnology equity research analyst at Morgan Stanley and Prudential Securities. Ms. Loewy has also leveraged her medical and financial expertise as a founding board member of the Global Genes Project and of the KCNQ2 Cure Alliance, both non-profit patient and advocacy organizations promoting education and research into rare disease. Ms. Loewy also currently sits on the board of CymaBay Therapeutics, Inc., PhaseBio Pharmaceuticals, Inc. and Phoenix Biotech Acquisition Corp. Ms. Loewy holds a B.A. from the University of California, Berkeley, and an M.B.A.\/M.S. from Carnegie Mellon University.<\/p>\n<p>\n        <strong>About eFFECTOR Therapeutics<\/strong>\n      <\/p>\n<p>eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs. eFFECTOR\u2019s STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase interacting kinase (MNK). The eIF4F complex is a central node where two of the most frequently mutated signaling pathways in cancer, the PI3K-AKT and RAS-MEK pathways, converge to activate the translation of select mRNA into proteins that are frequent culprits in key disease-driving processes. Each of eFFECTOR\u2019s product candidates is designed to act on a single protein that drives the expression of a network of functionally related proteins, including oncoproteins and immunosuppressive proteins in T cells, that together control tumor growth, survival and immune evasion. eFFECTOR\u2019s lead product candidate, tomivosertib, is a MNK inhibitor currently being evaluated in KICKSTART, a randomized, double-blind, placebo-controlled Phase 2b trial of tomivosertib in combination with pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC). Zotatifin, eFFECTOR\u2019s inhibitor of eIF4A, is currently being evaluated in Phase 2a expansion cohorts in certain biomarker-positive solid tumors, including ER+ breast cancer and KRAS-mutant NSCLC. eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E.<\/p>\n<p>\n        <strong>Contacts:<\/strong>\n      <\/p>\n<table align=\"center\" style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"vertical-align: middle\">\u00a0<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"vertical-align: middle\">\u00a0<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\n            <strong>Investors:<\/strong>\n          <\/td>\n<td style=\"vertical-align: bottom\">\u00a0\u00a0<\/td>\n<td style=\"vertical-align: top\">\u00a0<\/td>\n<td style=\"vertical-align: bottom\">\u00a0\u00a0<\/td>\n<td style=\"vertical-align: top\">\n            <strong>Media:<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">Christopher M. Calabrese<br \/>Managing Director<br \/>LifeSci Advisors<br \/>917-680-5608<br \/><a href=\"mailto:ccalabrese@lifesciadvisors.com\" rel=\"nofollow noopener\" target=\"_blank\">ccalabrese@lifesciadvisors.com<\/a><\/td>\n<td style=\"vertical-align: bottom\">\u00a0\u00a0<\/td>\n<td style=\"vertical-align: top\">Kevin Gardner<br \/>Managing Director<br \/>LifeSci Advisors<br \/>617-283-2856<br \/><a href=\"mailto:kgardner@lifesciadvisors.com\" rel=\"nofollow noopener\" target=\"_blank\">kgardner@lifesciadvisors.com<\/a><\/td>\n<td style=\"vertical-align: bottom\">\u00a0\u00a0<\/td>\n<td style=\"vertical-align: top\">Mike Tattory<br \/>Account Supervisor<br \/>LifeSci Communications<br \/>609-802-6265<br \/><a href=\"mailto:mtattory@lifescicomms.com\" rel=\"nofollow noopener\" target=\"_blank\">mtattory@lifescicomms.com<\/a><\/td>\n<\/tr>\n<\/table>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxOTU3MSM1ODA2NjkyIzIwODI1MTE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZGE4M2QzNTAtY2I4NS00Yzc2LThjYjgtMTk3Y2Y2N2ZlNzAxLTEwOTQwODI=\/tiny\/eFFECTOR-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) &#8212; eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (\u201cSTRIs\u201d) for the treatment of cancer, today announced the addition of Caroline Loewy to its Board of Directors and her election as Chair of the Board\u2019s Audit Committee. Concurrent with Ms. Loewy\u2019s appointment, current Board member John Smither has resigned from the Board. \u201cWe are tremendously fortunate to welcome Caroline given her extensive experience as an executive and board member at multiple biopharmaceutical companies,\u201d remarked Steve Worland, Ph.D., president and chief executive officer of eFFECTOR. \u201cBeyond her previous C-suite roles in operations and finance, Caroline also brings to eFFECTOR a wealth of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-appoints-caroline-loewy-to-board-of-directors\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;eFFECTOR Therapeutics Appoints Caroline Loewy to Board of Directors&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-783048","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>eFFECTOR Therapeutics Appoints Caroline Loewy to Board of Directors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-appoints-caroline-loewy-to-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"eFFECTOR Therapeutics Appoints Caroline Loewy to Board of Directors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) &#8212; eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (\u201cSTRIs\u201d) for the treatment of cancer, today announced the addition of Caroline Loewy to its Board of Directors and her election as Chair of the Board\u2019s Audit Committee. Concurrent with Ms. Loewy\u2019s appointment, current Board member John Smither has resigned from the Board. \u201cWe are tremendously fortunate to welcome Caroline given her extensive experience as an executive and board member at multiple biopharmaceutical companies,\u201d remarked Steve Worland, Ph.D., president and chief executive officer of eFFECTOR. \u201cBeyond her previous C-suite roles in operations and finance, Caroline also brings to eFFECTOR a wealth of &hellip; Continue reading &quot;eFFECTOR Therapeutics Appoints Caroline Loewy to Board of Directors&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-appoints-caroline-loewy-to-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-11T14:21:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxOTU3MSM1ODA2NjkyIzIwODI1MTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-appoints-caroline-loewy-to-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-appoints-caroline-loewy-to-board-of-directors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"eFFECTOR Therapeutics Appoints Caroline Loewy to Board of Directors\",\"datePublished\":\"2023-09-11T14:21:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-appoints-caroline-loewy-to-board-of-directors\\\/\"},\"wordCount\":730,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-appoints-caroline-loewy-to-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxOTU3MSM1ODA2NjkyIzIwODI1MTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-appoints-caroline-loewy-to-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-appoints-caroline-loewy-to-board-of-directors\\\/\",\"name\":\"eFFECTOR Therapeutics Appoints Caroline Loewy to Board of Directors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-appoints-caroline-loewy-to-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-appoints-caroline-loewy-to-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxOTU3MSM1ODA2NjkyIzIwODI1MTE=\",\"datePublished\":\"2023-09-11T14:21:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-appoints-caroline-loewy-to-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-appoints-caroline-loewy-to-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-appoints-caroline-loewy-to-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxOTU3MSM1ODA2NjkyIzIwODI1MTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxOTU3MSM1ODA2NjkyIzIwODI1MTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-appoints-caroline-loewy-to-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"eFFECTOR Therapeutics Appoints Caroline Loewy to Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"eFFECTOR Therapeutics Appoints Caroline Loewy to Board of Directors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-appoints-caroline-loewy-to-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"eFFECTOR Therapeutics Appoints Caroline Loewy to Board of Directors - Market Newsdesk","og_description":"SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) &#8212; eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (\u201cSTRIs\u201d) for the treatment of cancer, today announced the addition of Caroline Loewy to its Board of Directors and her election as Chair of the Board\u2019s Audit Committee. Concurrent with Ms. Loewy\u2019s appointment, current Board member John Smither has resigned from the Board. \u201cWe are tremendously fortunate to welcome Caroline given her extensive experience as an executive and board member at multiple biopharmaceutical companies,\u201d remarked Steve Worland, Ph.D., president and chief executive officer of eFFECTOR. \u201cBeyond her previous C-suite roles in operations and finance, Caroline also brings to eFFECTOR a wealth of &hellip; Continue reading \"eFFECTOR Therapeutics Appoints Caroline Loewy to Board of Directors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-appoints-caroline-loewy-to-board-of-directors\/","og_site_name":"Market Newsdesk","article_published_time":"2023-09-11T14:21:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxOTU3MSM1ODA2NjkyIzIwODI1MTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-appoints-caroline-loewy-to-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-appoints-caroline-loewy-to-board-of-directors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"eFFECTOR Therapeutics Appoints Caroline Loewy to Board of Directors","datePublished":"2023-09-11T14:21:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-appoints-caroline-loewy-to-board-of-directors\/"},"wordCount":730,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-appoints-caroline-loewy-to-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxOTU3MSM1ODA2NjkyIzIwODI1MTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-appoints-caroline-loewy-to-board-of-directors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-appoints-caroline-loewy-to-board-of-directors\/","name":"eFFECTOR Therapeutics Appoints Caroline Loewy to Board of Directors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-appoints-caroline-loewy-to-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-appoints-caroline-loewy-to-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxOTU3MSM1ODA2NjkyIzIwODI1MTE=","datePublished":"2023-09-11T14:21:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-appoints-caroline-loewy-to-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-appoints-caroline-loewy-to-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-appoints-caroline-loewy-to-board-of-directors\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxOTU3MSM1ODA2NjkyIzIwODI1MTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxOTU3MSM1ODA2NjkyIzIwODI1MTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-appoints-caroline-loewy-to-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"eFFECTOR Therapeutics Appoints Caroline Loewy to Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/783048","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=783048"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/783048\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=783048"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=783048"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=783048"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}